We have a multi‐channel education and support programme for local health economies (and patients and clinicians) to ensure that the UK diabetes community is able to benefit from this reimbursement decision in the most responsible way possible.
We are in direct communication with LHEs and the wider healthcare economy to ensure that those intensively using insulin are given access to this innovative technology in the months and years ahead.